Indolent Systemic Mastocytosis clinical trials

Explore recruiting indolent systemic mastocytosis clinical trials.

Recruiting indolent systemic mastocytosis studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Indolent Systemic Mastocytosis trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis

Portugal, Denmark, Sweden, France, Spain, Germany +9 more

Phase II and Phase III (Integrated) EU CTIS Study details

A Phase 2 Multicenter Study of TL-895 in Subjects with Myelofibrosis, Indolent Systemic Mastocytosis, Monoclonal Mast Cell Activation Syndrome, or Non-Monoclonal Mast Cell Activation Syndrome

Germany, Italy, Spain, Belgium, Bulgaria, France +3 more

Therapeutic exploratory (Phase II) EU CTIS Study details

The use of dupilumab in treatment of indolent systemic mastocytosis with skin involvement

Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

Hydroxychloroquine in isolated cutaneous mastocytosis patients or indolent systemic mastocytosis with associated skin involvement patients: proof of concept study (HCQMa)

France

Therapeutic confirmatory (Phase III) EU CTIS Study details

A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU 285), a Selective KIT Mutation-Targeted Tyrosine Kinase Inhibitor, in Indolent and Smoldering Systemic Mastocytosis with Symptoms Inadequately Controlled with Standard Therapy

France, Netherlands, Denmark, Sweden, Germany, Italy +3 more